A new global dementia report released on September 21 puts a less visible part of medical progress under the spotlight: the people who volunteer for research. As new tests and treatments attract attention, Alzheimer’s Disease International is asking how clinical trials can become more accessible, representative and understandable to the families they are intended to help.

The World Alzheimer Report 2026, published on World Alzheimer’s Day, examines recruitment, participation, ethics and the experiences of people involved in studies. Its central subject is the path from a promising scientific idea to evidence that can guide care. It is not an announcement that dementia has been cured.

A large pipeline still has to become evidence

In its report-launch briefing, ADI cites 158 drugs in 192 trials and says thousands of participants are needed globally. Those figures describe research activity, not 158 medicines ready for routine use. A single candidate can be studied in more than one trial, and an experimental treatment can fail to deliver sufficient benefit or prove unsuitable because of its risks.

That distinction matters when reading a breakthrough headline. The number of projects shows how much work is under way; the results establish whether a particular intervention helps. Families need information about the actual study, including its participants, comparison group, duration and outcomes, before a headline can be translated into a meaningful question for their clinician.

What researchers are testing

The US National Institute on Aging explains that clinical trials test interventions, while observational studies follow people and collect information without assigning an experimental treatment. Research can investigate diagnosis, prevention, daily functioning and support for carers, as well as medicines.

Drug trials generally move through stages: early work examines safety and dosage, later studies assess effectiveness and risks in larger groups, and monitoring continues after approval. Being enrolled therefore does not necessarily mean receiving a treatment already known to work. Some trials randomly assign participants to different groups so that researchers can make a fair comparison.

For a reader considering research, the first useful question is what the study is trying to establish. A memory assessment, a study of family support and a trial of an experimental medicine can involve very different commitments. The word “research” alone does not explain what will happen at an appointment.

Participation has to be practical as well as possible

ADI’s report places global representation and retention alongside scientific progress. Recruiting someone is only the beginning: a study also needs people to remain involved long enough for its findings to be useful. A design that looks manageable on paper may be difficult for someone balancing work, caring responsibilities and repeated journeys.

NIA advises prospective participants to ask about travel, costs, visit frequency, possible side effects and whether a study partner is needed. Families should also establish how the research team will communicate with their usual doctor, what happens if health deteriorates, and whether any study treatment remains available after the trial ends.

Writing those answers down can help turn an emotional decision into a practical discussion. An invitation to learn about a study is an opportunity to ask questions; it is not a commitment to enrol. Eligibility is specific to each protocol, so being unsuitable for one project does not answer whether another could be appropriate.

Consent and ordinary care remain essential

The US Food and Drug Administration’s participation guidance stresses that joining is voluntary and that participants can leave. The informed-consent process should explain the study before someone agrees. Safety requirements and detailed protocols reduce risk, but they do not convert an experimental intervention into a guaranteed personal benefit.

The wider need is substantial. The World Health Organization estimates that 57 million people were living with dementia in 2021, with more than 60% in low- and middle-income countries. That is a dated global estimate, not a new count for 2026. WHO also emphasizes that dementia is not an inevitable consequence of ageing and that support can improve daily life.

Anyone concerned about persistent changes in memory or everyday functioning should seek a clinical assessment rather than use a trial advertisement as a diagnosis. Today’s report offers a reason to learn more about research, while care planning, support for carers and the needs of the person living with dementia remain immediate priorities.